info@seagull-health.com
SeagullHealth
search
pemazyre(pemigatinib)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
pemazyre(pemigatinib) Instructions:Uses,Dosage, Side Effects
Pemigatinib is a novel drug used for the treatment of specific diseases. Correct administration methods and dosages are crucial for the drug's efficacy and safety.
During the use of pemigatinib, attention should be paid to drug interactions with strong and moderate CYP3A inducers as well as strong and moderate CYP3A inhibitors.
Pemigatinib is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma that is unresectable, has been previously treated, and harbors fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements as detected by an FDA-approved test.
2. Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
Pemigatinib is indicated for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLN) harboring fibroblast growth factor receptor 1 (FGFR1) rearrangements.
The recommended dose of pemigatinib is 13.5 mg, taken orally once daily for 14 consecutive days, followed by a 7-day break from treatment. This constitutes a 21-day cycle. Treatment should be continued until disease progression occurs or unacceptable toxicities develop.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
